Annet Kirabo, D.V.M., Ph.D., FAHA, professor of medicine at Vanderbilt Health, will receive the 2026 Joseph A. Vita Award from the American Heart Association at its Scientific Sessions in Chicago, Nov. 6-9, 2026. The award, presented during the Opening Session on Nov. 7, recognizes a scientist whose research has significantly advanced cardiovascular biology or health within the past five years and whose work has been published in the Association's journals. The selection by the editors-in-chief of the Association's 14 peer-reviewed journals underscores the transformative nature of Kirabo's discoveries.
Kirabo's research revealed how immune activation and inflammation contribute to high blood pressure, a finding that represents a paradigm shift in cardiovascular biology. Her work demonstrated that lipid oxidation-derived protein adducts act as neoantigens, triggering antigen-presenting cell activation, T-cell responses, vascular dysfunction, and hypertension. This fundamentally changed the understanding of blood pressure regulation and opened new avenues for therapeutic intervention, including targets like isolevuglandins and sodium-sensing pathways in immune cells.
The implications are profound. Hypertension affects billions worldwide and is a leading cause of heart disease, stroke, and kidney failure. By identifying immune mechanisms as drivers of hypertension, Kirabo's work suggests that immunomodulatory therapies could prevent or treat cardiovascular and kidney diseases, moving beyond traditional approaches that focus on lifestyle and existing drugs. Her laboratory now integrates immunology, vascular biology, genomics, metabolomics, and single-cell technologies to translate these discoveries into patient care.
Manesh R. Patel, M.D., FAHA, the American Heart Association's 2026-2027 volunteer president, said, “Her pioneering discoveries represent a paradigm shift in cardiovascular biology, reshaping our understanding of hypertension by revealing how immune activation and inflammation drive cardiovascular disease.” Patel noted that Kirabo's work has uncovered potential therapeutic targets that could lead to new prevention and treatment strategies.
Kirabo's contributions extend beyond the lab. She has been an active Heart Association volunteer since 2009, serving on the Council on Hypertension Communications Committee and the Council Operations Committee. She has been on the editorial board of the Hypertension journal since 2018 and an associate editor of Circulation Research since 2019. Her mentorship of dozens of trainees who have become independent investigators ensures the longevity of her impact.
The award is named after Joseph A. Vita, M.D., founding editor of the Journal of the American Heart Association (JAHA). It celebrates research that changes the direction of cardiovascular science. Kirabo's recognition highlights the growing importance of immunology in cardiovascular research and the potential for novel therapies that address root causes of hypertension.
With more than 230 scientific publications and sustained NIH funding, Kirabo's work continues to influence investigators globally. Her journey from Makerere University in Uganda to leading an internationally recognized program at Vanderbilt exemplifies the global nature of scientific discovery. As the American Heart Association notes, additional resources, including multimedia, are available on the right column of the release link.
The 2026 Joseph A. Vita Award not only honors Kirabo's past achievements but also signals a future where immune-based therapies could transform hypertension management, offering hope to millions affected by cardiovascular and kidney diseases.
